Anika Therapeutics Net Debt Growth & History (ANIK)
Anika Therapeutics's net debt was −$31.2M for fiscal 2025.
View full Anika Therapeutics company overviewAnika Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$31.2M | −$1.5M | — |
| 2024 | 2024-12-31 | −$29.7M | $11.3M | — |
| 2023 | 2023-12-31 | −$41.0M | $16.5M | — |
| 2022 | 2022-12-31 | −$57.5M | $17.6M | — |
| 2021 | 2021-12-31 | −$75.1M | −$1.7M | — |
| 2020 | 2020-12-31 | −$73.4M | $61.5M | — |
| 2019 | 2019-12-31 | −$135.0M | — | — |
| 2012 | 2012-12-31 | −$34.5M | −$9.9M | — |
| 2011 | 2011-12-31 | −$24.6M | −$9.2M | — |
| 2010 | 2010-12-31 | −$15.4M | — | — |
Anika Therapeutics quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$13.2M | $15.0M | — |
| Q1 2026 | 2026-03-31 | −$15.3M | $12.7M | — |
| Q4 2025 | 2025-12-31 | −$31.2M | −$1.5M | — |
| Q3 2025 | 2025-09-30 | −$33.5M | $1.4M | — |
| Q2 2025 | 2025-06-30 | −$28.2M | $6.6M | — |
| Q1 2025 | 2025-03-31 | −$27.9M | $12.2M | — |
| Q4 2024 | 2024-12-31 | −$29.7M | $11.3M | — |
| Q3 2024 | 2024-09-30 | −$34.8M | $8.6M | — |
| Q2 2024 | 2024-06-30 | −$34.7M | $2.5M | — |
| Q1 2024 | 2024-03-31 | −$40.2M | $11.3M | — |
| Q4 2023 | 2023-12-31 | −$41.0M | $16.5M | — |
| Q3 2023 | 2023-09-30 | −$43.4M | $15.2M | — |
| Q2 2023 | 2023-06-30 | −$37.3M | $24.4M | — |
| Q1 2023 | 2023-03-31 | −$51.5M | $20.0M | — |
| Q4 2022 | 2022-12-31 | −$57.5M | $17.6M | — |
| Q3 2022 | 2022-09-30 | −$58.6M | $10.3M | — |
| Q2 2022 | 2022-06-30 | −$61.7M | $13.5M | — |
| Q1 2022 | 2022-03-31 | −$71.5M | $2.4M | — |
| Q4 2021 | 2021-12-31 | −$75.1M | −$1.7M | — |
| Q3 2021 | 2021-09-30 | −$68.8M | −$12.8M | — |
| Q2 2021 | 2021-06-30 | −$75.1M | −$31.9M | — |
| Q1 2021 | 2021-03-31 | −$73.9M | −$32.0M | — |
| Q4 2020 | 2020-12-31 | −$73.4M | $61.5M | — |
| Q3 2020 | 2020-09-30 | −$56.1M | $24.6M | — |
| Q2 2020 | 2020-06-30 | −$43.2M | $3.1M | — |
| Q1 2020 | 2020-03-31 | −$41.9M | $30.3M | — |
| Q4 2019 | 2019-12-31 | −$135.0M | — | — |
| Q3 2019 | 2019-09-30 | −$80.7M | — | — |
| Q2 2019 | 2019-06-30 | −$46.3M | — | — |
| Q1 2019 | 2019-03-31 | −$72.2M | — | — |
| Q3 2013 | 2013-09-30 | −$55.7M | −$25.8M | — |
| Q2 2013 | 2013-06-30 | −$45.3M | −$17.8M | — |
| Q1 2013 | 2013-03-31 | −$41.8M | −$18.6M | — |
| Q4 2012 | 2012-12-31 | −$34.5M | −$9.9M | — |
| Q3 2012 | 2012-09-30 | −$29.9M | −$12.4M | — |
| Q2 2012 | 2012-06-30 | −$27.5M | −$12.7M | — |
| Q1 2012 | 2012-03-31 | −$23.2M | — | — |
| Q4 2011 | 2011-12-31 | −$24.6M | −$9.2M | — |
| Q3 2011 | 2011-09-30 | −$17.4M | — | — |
| Q2 2011 | 2011-06-30 | −$14.8M | — | — |
| Q4 2010 | 2010-12-31 | −$15.4M | — | — |
Anika Therapeutics net debt trends
Over the last five fiscal years, Anika Therapeutics's net debt increased from −$73.4M to −$31.2M, a change of $42.2M. The latest reported quarter, Q2 2026, shows −$13.2M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anika Therapeutics source filings ↗